Jason Mast

Here, Vought doesn’t dispute slow-walking release of NIH grants from congressionally appropriated funds so that they can be cancelled in a couple of months through pocket rescission thereby bypassing congress to enact huge cuts to NIH research.

$SRPT The death referred to in the FDA statement may be the boy from Brazil who was disclosed earlier today by Brazilian authorities. Details in that announcement were scant, but the timing of that death and age described in the FDA statement fit what STAT had learned about…

Must-listen episode this week that literally brings DMD to life... just wow... Sure seems like FDA needs to figure out a way to allow elevidys back on the market, at least perhaps for boys who are already responding (and with appropriate warnings). Damn.

$SRPT Fully updated story w/ Brazil, Japan suspensions, Elevidys patient death in Brazil said to be due to influenza Europe moves to reject embattled Duchenne muscular dystrophy gene therapy statnews.com/2025/07/25/ele… via @DrewQJoseph

Europe moves to reject embattled Duchenne muscular dystrophy gene therapy statnews.com/2025/07/25/ele… via @DrewQJoseph $RHHBY $SRPT

As the FDA and Sarepta clash over what to do after the deaths of three patients from its gene therapies, parents of young children — some preparing to be dosed this summer — have been caught in between statnews.com/2025/07/24/duc…

As Sarepta, FDA tangle over Duchenne therapy, families are caught in the middle, ⁦@Jasonmmast⁩ writes statnews.com/2025/07/24/duc…

For many Duchenne families, halt to Sarepta $SRPT gene therapy treatments is heartbreak upon heartbreak statnews.com/2025/07/24/duc… My colleague @Jasonmmast with more reporting on the patient/physician perspective.

On this week's podcast: we bring on the mother of a boy with Duchenne muscular dystrophy to talk about the impact of Sarepta's gene therapy halt. w/ @adamfeuerstein, @ADeAngelis_bio statnews.com/2025/07/24/rea…

Solid tumors have challenged CAR-T developers. This biotech raised $216 million to test a new approach statnews.com/2025/07/23/sea… via @statnews

This is a fairly shocking detail in @adamfeuerstein and @Jasonmmast's latest story on why the FDA acted when it did in response to most recent $SRPT patient death:

Breaking: In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy statnews.com/2025/07/21/sar… via @statnews @adamfeuerstein @Jasonmmast

BREAKING: In surprise reversal, Sarepta $SRPT says it will pause shipments of Duchenne gene therapy statnews.com/2025/07/21/sar… via @Jasonmmast and me

The lesson of Sarepta Therapeutics vs. the FDA is clear, @matthewherper writes: In medicine, listening to critics, and responding with data, is the surest path forward. statnews.com/2025/07/21/sar…

Alarming article about overly aggressive organ procurement. I believe these cases represent a tiny fraction of organ donations but they cast a shadow on the whole effort. nytimes.com/2025/07/20/us/… via @NYTimes

Read this updated story on $srpt with comments from Peter Marks and ⁦@daphnezohar⁩ — by ⁦@adamfeuerstein⁩ and ⁦@Jasonmmast⁩ statnews.com/2025/07/18/sar…

Peter Marks, the FDA official who overruled staff to approve the drug, told STAT he agreed "it makes a fair amount of sense" to pause shipments after recent deaths. "To get a better handle on the issues before you proceed, if you decide to proceed.”

Peter Marks, the FDA official who overruled his own staff to approve Sarepta's Duchenne gene therapy, told STAT he agreed with the decision to pause shipments after recent deaths. “It does seem like it makes a fair amount of sense to get a better handle on the issues before…